Thrombolytic Therapy: Clot Dissolution for Acute Ischemic Events

Thrombolytic therapy (fibrinolysis) uses plasminogen activators to dissolve occlusive thrombi, restoring perfusion.

Indications (Time-Critical)

  • Acute ischemic stroke: IV alteplase ≤4.5 hr (selected ≤9 hr with imaging)
  • STEMI: If PCI unavailable ≤12 hr; door-to-needle ≤30 min
  • Massive PE: Hemodynamic instability
  • Acute limb ischemia / arterial thrombosis

Agents

AgentSourceMechanismKey Feature
Alteplase (tPA)RecombinantFibrin-specific: binds fibrin → converts plasminogen → plasminStandard for stroke/STEMI
Tenecteplase (TNK)Modified tPALonger half-life, bolus dosingSTEMI preferred; stroke trials ongoing
ReteplaseModified tPALess fibrin-specific, double bolusSTEMI
StreptokinaseBacterialNon-fibrin-specific; antigenicLow cost; not for repeat use
UrokinaseHuman kidney / recombinantDirect plasminogen activatorCatheter-directed thrombosis

Major Risk

Intracranial hemorrhage (ICH): ~3–6% in stroke; higher with age, HTN, large infarct, anticoagulation.

Contraindications

  • Active bleeding, recent surgery/trauma, hemorrhagic stroke, aortic dissection, severe uncontrolled HTN

Benefit-risk assessment must be rapid and documented.

Blood Disorders - Related Articles